0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Promising new antiherpes agent being tested in humans

JAMA. 1978;240(21):2231. doi:10.1001/jama.1978.03290210013001.
Text Size: A A A
Published online

ABSTRACT

The search for a drug to combat the herpesviruses has involved a long battle. Last year the efficacy of vidarabine against herpes encephalitis was reported (JAMA MEDICAL NEWS 238:1121 [Sept 12] 1977).

This year, a new antiviral compound called 9-(2hydroxyethoxymethyl) guanine, also known as BW 248U or Zovirax, offers some hope.

Its antiviral activity against three herpesviruses— herpes simplex virus, varicella zoster virus, and the Epstein-Barr virus—in cell culture studies was described at a recent meeting of the American Society of Microbiology. According to Gertrude Elion, PhD, of the Burroughs Wellcome Laboratories, which developed the drug, it is now being tested in humans.

The company has filed three Investigational New Drug (IND) applications with the Food and Drug Administration. One is for use of BW 248U in a petrolatum-base ointment for ophthalmic herpes infections. Another is for studies of intravenous administration of the drug to determine dose ranges relating to

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();